Choline Chloride Market Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "Choline Chloride Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering. The global ...

(RTTNews) - Protara Therapeutics, Inc. (TARA) announced the FDA has granted Fast Track designation to Intravenous Choline Chloride, the investigational IV phospholipid substrate replacement ...

IV Choline Chloride is an investigational, intravenous phospholipid substrate replacement therapy in development for patients receiving parenteral support (PS).

FDA fast tracks Protara's choline chloride therapyThe FDA's Fast Track program allows for more frequent interactions with the FDA during drug development, eligibility for accelerated approval and ...

Based on feedback from the FDA, Protara intends to assess the safety and efficacy of IV Choline Chloride in THRIVE-3, a seamless registrational Phase 2b/3 trial with dose confirmation followed by a ...

78% of patients dependent on parenteral support were choline deficient, with 63% of these patients demonstrating liver dysfunction, including steatosis, cholestasis, and hepatobiliary injury IV ...

Knowing that of the two substances only choline chloride is good at absorbing microwaves, the researchers submerged the battery waste material in the solvent and blasted it with microwave radiation.

The analysts forecast the global choline chloride market to exhibit a CAGR of 5.67% during the period 2019-2024.The report covers the present scenario and the growth prospects of the global choline ...

IV Choline Chloride has shown promise in previous studies by increasing plasma choline concentrations and improving steatosis, a marker of liver injury, in PN patients. This investigational therapy ...

In previous studies, treatment with IV Choline Chloride successfully increased plasma choline concentrations in patients on PN and was also shown to improve steatosis, a key marker of liver injury.